Date of Award
Winter 1-2026
Document Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Department
Pharmaceutical Sciences
First Advisor
Kamaljit Kaur
Second Advisor
Jennifer Totonchy
Third Advisor
Hamidreza Montazeri Aliabadi
Fourth Advisor
Madeline Dintzner
Fifth Advisor
Rennolds Ostrom
Abstract
A significant problem faced in oncology is the lack of chemotherapeutic agents that are tumor site-specific, resulting in reduced therapeutic efficacy and unintended infliction of harm to surrounding healthy tissues and cells that often lead to serious side effects. Current strategies being explored to circumvent this issue aim to refine delivery of chemotherapeutic agents specifically to tumor sites, which may be achieved via conjugation of these agents to biomarker-specific ligands. This forms the foundation of ligand-targeted drug delivery. Among different breast cancers, treatment of the triple-negative breast cancer (TNBC) subtype has been particularly challenging, largely due to the absence of a well-defined biomarker to exploit for targeted drug delivery. This has substantially limited the number of effective TNBC treatment options, funneling down primarily to conventional chemotherapy, the long-standing standard of care. The scope of this dissertation covers the peptide–drug conjugate (PDC) therapeutic modality. The findings herein delineate novel ligands, targets, and PDCs for effectively targeting TNBC.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Recommended Citation
Yao, S-J. Evaluation of Peptides and Peptide–Doxorubicin Conjugates Designed and Synthesized for Targeting Triple-Negative Breast Cancer via Cell-Surface Receptors. [dissertation]. Irvine, CA: Chapman University; 2026. https://doi.org/10.36837/chapman.000716
Included in
Cancer Biology Commons, Medicinal and Pharmaceutical Chemistry Commons, Oncology Commons, Other Pharmacy and Pharmaceutical Sciences Commons, Pharmaceutics and Drug Design Commons